Company
Artrya Ltd
ASX:AYA
Artrya Limited is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. The company's proprietary software analyses coronary CT scans to Identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently.
37 stories
The smart money in medicine: the world's biggest killer
Coronary artery disease affects 126 million people globally and nine million will die from it annually – more than from any other cause. No wonder then that medtechs are channelling research money into prevention, early intervention and tre
The rise of artificial intelligence in healthcare
With the vast data sets now available to it, artificial intelligence is moving into a new phase of development and nowhere is this change more pronounced than in the healthcare sector.
Artrya gains UK regulatory approval for Salix Coronary Anatomy product
MD and CEO John Barrington AM said UK regulatory approval was a landmark moment. “Our business activities in the UK are advanced and Artrya is well positioned to take advantage of the regulatory approval in this significant market."
Artrya set to market Salix V2.0 Software into Europe
“We are pleased to receive this significant regulatory approval for what is a substantial future market opportunity,’’ Artrya managing director and CEO John Barrington AM said.
June quarter: biotech companies buck trend that says sector moves slowly
Patience pays off in the biotech world, but the June quarter was pretty fast-moving for a clutch of Australian companies as trials yielded results, patents and manufacturing deals were inked and the odd acquisition was harnessed.
Artrya appoints US healthcare leader as non-executive director
New non-executive director Dr Jacque Sokolov is chairman and president of Artrya USA Inc and chairs the company’s Clinical Advisory Board.
A theatre of human innovation: Artrya
For medtech entrepreneur and Artrya Ltd CEO John Barrington, every good solution to a problem starts with a clean sheet of paper and a little bit of human ingenuity.
Artya appoints chief medical officer to further strengthen US expansion
Dr Jacob Agris' experience will be vital to Artya's aims in combating coronary disease and in being a strategic partner and advisor to the CEO and leadership team.
Artrya continues to push forward around the world despite FDA setback
Artrya has regulatory processes underway in several global markets that are independent of the FDA .
Artrya shakes hands on first US clinical partnership with renowned heart hospital
Under an initial agreement, Huntsville Heart Center and Artyra will compare patient cardiac CT scans read by experts to those read by artificial intelligence (AI)-based technology.
IPO advent calendar: the 31 stocks set to hit the ASX in December
Companies have flocked to the ASX this year, with a barrage of stocks hitting the local share market in the last 11 months ... and more to come.
Artrya gets to the heart of AI with ASX listing, $40 million IPO
Fresh from its ASX debut, AYA’s mission is simple: it’s out to more accurately and less invasively detect signs of heart disease with the power of artificial intelligence (AI).
Sheffield Resources, Radar Iron, Kidman Resources, Fortis Mining, Glory Resources gain in IPO review
With 19 resource IPO's hitting the ASX boards around one year ago - Proactive Investors Australia are here to provide a performance review over the turbulent 2011. Find out which companies investors are supporting, and selling.